NASDAQ:NVUS - Novus Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.63 -0.08 (-4.68 %) (As of 05/26/2019 10:55 AM ET)Previous Close$1.63Today's Range$1.63 - $1.8452-Week Range$1.52 - $8.61Volume61,987 shsAverage Volume45,186 shsMarket Capitalization$15.38 millionP/E RatioN/ADividend YieldN/ABeta3.32 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California. Receive NVUS News and Ratings via Email Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVUS Previous Symbol CUSIPN/A CIK1404281 Webhttp://novustherapeutics.com/ Phone949-238-8090Debt Debt-to-Equity Ratio0.03 Current Ratio3.18 Quick Ratio3.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book1.55Profitability EPS (Most Recent Fiscal Year)($1.56) Net Income$-14,060,000.00 Net MarginsN/A Return on Equity-100.64% Return on Assets-88.15%Miscellaneous EmployeesN/A Outstanding Shares9,434,000Market Cap$15.38 million Next Earnings Date8/6/2019 (Estimated) OptionableNot Optionable Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions What is Novus Therapeutics' stock symbol? Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS." How were Novus Therapeutics' earnings last quarter? Novus Therapeutics Inc (NASDAQ:NVUS) posted its quarterly earnings data on Tuesday, May, 14th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.04. View Novus Therapeutics' Earnings History. When is Novus Therapeutics' next earnings date? Novus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Novus Therapeutics. What price target have analysts set for NVUS? 1 equities research analysts have issued twelve-month price objectives for Novus Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Novus Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 513.5% from the stock's current price. View Analyst Price Targets for Novus Therapeutics. What is the consensus analysts' recommendation for Novus Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novus Therapeutics. Has Novus Therapeutics been receiving favorable news coverage? Media coverage about NVUS stock has trended negative on Sunday, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novus Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the near future. Who are some of Novus Therapeutics' key competitors? Some companies that are related to Novus Therapeutics include Eyenovia (EYEN), Alimera Sciences (ALIM), Aquinox Pharmaceuticals (AQXP), Novan (NOVN), Agile Therapeutics (AGRX), Avadel Pharmaceuticals (AVDL), Seelos Therapeutics (SEEL), IVERIC bio (ISEE), Ophthotech (OPHT), Proteostasis Therapeutics (PTI), AEterna Zentaris (AEZS), Oramed Pharmaceuticals (ORMP), Moleculin Biotech (MBRX), CTI BioPharma (CTIC) and Zosano Pharma (ZSAN). What other stocks do shareholders of Novus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Progenics Pharmaceuticals (PGNX), PTC Therapeutics (PTCT), Tonix Pharmaceuticals (TNXP), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Verastem (VSTM) and Anavex Life Sciences (AVXL). Who are Novus Therapeutics' key executives? Novus Therapeutics' management team includes the folowing people: Mr. Gregory J. Flesher, CEO & Director (Age 49)Dr. Catherine C. Turkel, Pres (Age 58)Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 54) Who are Novus Therapeutics' major shareholders? Novus Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.14%), National Asset Management Inc. (1.69%), Morgan Stanley (0.13%) and Seelaus Asset Management LLC (0.11%). Company insiders that own Novus Therapeutics stock include Catherine C Turkel, Erez Chimovits, Gregory J Flesher, Jon Kuwahara and Lifesci Index Partners Llc. View Institutional Ownership Trends for Novus Therapeutics. Which institutional investors are selling Novus Therapeutics stock? NVUS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold Novus Therapeutics company stock in the last year include Catherine C Turkel, Gregory J Flesher, Jon Kuwahara and Lifesci Index Partners Llc. View Insider Buying and Selling for Novus Therapeutics. Which institutional investors are buying Novus Therapeutics stock? NVUS stock was bought by a variety of institutional investors in the last quarter, including National Asset Management Inc., Morgan Stanley and Seelaus Asset Management LLC. Company insiders that have bought Novus Therapeutics stock in the last two years include Catherine C Turkel and Erez Chimovits. View Insider Buying and Selling for Novus Therapeutics. How do I buy shares of Novus Therapeutics? Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novus Therapeutics' stock price today? One share of NVUS stock can currently be purchased for approximately $1.63. How big of a company is Novus Therapeutics? Novus Therapeutics has a market capitalization of $15.38 million. The biopharmaceutical company earns $-14,060,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. What is Novus Therapeutics' official website? The official website for Novus Therapeutics is http://novustherapeutics.com/. How can I contact Novus Therapeutics? Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected] MarketBeat Community Rating for Novus Therapeutics (NASDAQ NVUS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 190 (Vote Outperform)Underperform Votes: 180 (Vote Underperform)Total Votes: 370MarketBeat's community ratings are surveys of what our community members think about Novus Therapeutics and other stocks. Vote "Outperform" if you believe NVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVUS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: QQQ ETF Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.